Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVS NASDAQ:ETON NASDAQ:IPSC NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$7.35+2.7%$6.38$2.54▼$10.00$533.52M0.571.04 million shs1.13 million shsETONEton Pharmaceuticals$18.46-0.4%$18.54$7.58▼$23.00$497.21M1.16330,087 shs145,407 shsIPSCCentury Therapeutics$0.58-2.2%$0.52$0.34▼$1.83$50.97M1.78910,404 shs879,726 shsTNGXTango Therapeutics$7.49-0.5%$7.51$1.03▼$9.70$837.79M1.673.67 million shs6.31 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals+2.65%+4.40%+13.43%+56.05%-2.78%ETONEton Pharmaceuticals-0.43%+1.54%-7.38%+19.87%+127.06%IPSCCentury Therapeutics-2.15%+6.45%+19.15%-7.72%-62.27%TNGXTango Therapeutics-0.53%-17.05%-3.97%+9.82%+19.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$7.35+2.7%$6.38$2.54▼$10.00$533.52M0.571.04 million shs1.13 million shsETONEton Pharmaceuticals$18.46-0.4%$18.54$7.58▼$23.00$497.21M1.16330,087 shs145,407 shsIPSCCentury Therapeutics$0.58-2.2%$0.52$0.34▼$1.83$50.97M1.78910,404 shs879,726 shsTNGXTango Therapeutics$7.49-0.5%$7.51$1.03▼$9.70$837.79M1.673.67 million shs6.31 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals+2.65%+4.40%+13.43%+56.05%-2.78%ETONEton Pharmaceuticals-0.43%+1.54%-7.38%+19.87%+127.06%IPSCCentury Therapeutics-2.15%+6.45%+19.15%-7.72%-62.27%TNGXTango Therapeutics-0.53%-17.05%-3.97%+9.82%+19.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 2.60Moderate Buy$13.7587.07% UpsideETONEton Pharmaceuticals 2.40Hold$29.6760.71% UpsideIPSCCentury Therapeutics 2.60Moderate Buy$3.75549.58% UpsideTNGXTango Therapeutics 2.67Moderate Buy$11.0046.86% UpsideCurrent Analyst Ratings BreakdownLatest IPSC, ETON, CRVS, and TNGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025CRVSCorvus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025IPSCCentury TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025TNGXTango TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025TNGXTango TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $12.0010/13/2025CRVSCorvus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.0010/13/2025CRVSCorvus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.0010/8/2025CRVSCorvus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IPSCCentury TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025TNGXTango TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AETONEton Pharmaceuticals$58.18M8.51N/AN/A$0.94 per share19.64IPSCCentury Therapeutics$6.59M7.57N/AN/A$1.90 per share0.30TNGXTango Therapeutics$42.07M19.81N/AN/A$1.86 per share4.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A36.92N/A-7.10%-0.73%-0.22%11/6/2025 (Estimated)IPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-11.53%-6.94%11/4/2025 (Estimated)TNGXTango Therapeutics-$130.30M-$1.33N/AN/AN/A-599.11%-79.72%-49.30%11/5/2025 (Estimated)Latest IPSC, ETON, CRVS, and TNGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CRVSCorvus Pharmaceuticals-$0.14N/AN/AN/AN/AN/A11/6/2025Q3 2025ETONEton Pharmaceuticals$0.13N/AN/AN/A$20.47 millionN/A11/5/2025Q3 2025TNGXTango Therapeutics-$0.07N/AN/AN/A$41.35 millionN/A11/4/2025Q3 2025IPSCCentury Therapeutics-$0.39N/AN/AN/AN/AN/A8/14/2025Q2 2025IPSCCentury Therapeutics-$0.38-$0.38N/A-$0.38$0.03 millionN/A8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 million8/5/2025Q2 2025TNGXTango Therapeutics-$0.35-$0.35N/A-$0.35$6.41 million$3.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A8.918.91ETONEton Pharmaceuticals1.141.771.16IPSCCentury TherapeuticsN/A10.7210.72TNGXTango TherapeuticsN/A4.754.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%ETONEton Pharmaceuticals27.86%IPSCCentury Therapeutics50.20%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals28.50%ETONEton Pharmaceuticals16.03%IPSCCentury Therapeutics5.00%TNGXTango Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3074.51 million53.28 millionOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableIPSCCentury Therapeutics17086.39 million82.07 millionOptionableTNGXTango Therapeutics90111.26 million102.92 millionOptionableIPSC, ETON, CRVS, and TNGX HeadlinesRecent News About These CompaniesGuggenheim Maintains Tango Therapeutics (TNGX) Buy RecommendationOctober 25 at 3:54 AM | msn.comTango Therapeutics price target raised to $12 from $10 at GuggenheimOctober 24 at 3:22 PM | msn.comTango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month High - What's Next?October 24 at 10:46 AM | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Price Target Raised to $12.00October 24 at 8:09 AM | marketbeat.comTango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers TranscriptOctober 23 at 6:00 PM | seekingalpha.comTango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers - SlideshowOctober 23 at 2:38 PM | seekingalpha.comTango Therapeutics stock falls after $210 million share offeringOctober 23 at 12:34 PM | investing.comTango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million FinancingOctober 23 at 12:34 PM | finanznachrichten.deTango Therapeutics prices 21M shares at $8.66 in underwritten offeringOctober 23 at 12:34 PM | msn.comTango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer TherapyOctober 23 at 12:34 PM | msn.comTango Therapeutics Stock Falls After $210 Million Equity OfferingOctober 23 at 12:34 PM | tokenist.comTTango Therapeutics stock rises after strong pancreatic cancer trial dataOctober 23 at 12:34 PM | za.investing.comTango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund AdvancementOctober 23 at 11:17 AM | benzinga.comAssessing Tango Therapeutics (TNGX) Valuation After 170% Share Price Rally and Recent PullbackOctober 23 at 7:33 AM | finance.yahoo.comTango Therapeutics Announces $225 Million FinancingOctober 23 at 7:33 AM | markets.businessinsider.comTango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted CancersOctober 23 at 7:33 AM | markets.businessinsider.comTango Therapeutics Announces $225 Million FinancingOctober 23 at 7:20 AM | globenewswire.comTango Therapeutics granted orphan designation for treatment of malignant gliomaOctober 16, 2025 | msn.comTango Therapeutics (NASDAQ:TNGX) Reaches New 1-Year High - Here's WhyOctober 14, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Stock Price Up 13.9% - Should You Buy?October 13, 2025 | marketbeat.comTango Therapeutics' (TNGX) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSC, ETON, CRVS, and TNGX Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$7.35 +0.19 (+2.65%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$7.32 -0.03 (-0.39%) As of 10/24/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Eton Pharmaceuticals NASDAQ:ETON$18.46 -0.08 (-0.43%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$18.46 0.00 (0.00%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Century Therapeutics NASDAQ:IPSC$0.58 -0.01 (-2.15%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$0.60 +0.02 (+3.76%) As of 10/24/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Tango Therapeutics NASDAQ:TNGX$7.49 -0.04 (-0.53%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$7.49 +0.00 (+0.05%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
